Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 9:9:1013846.
doi: 10.3389/fmed.2022.1013846. eCollection 2022.

Cutaneous vasculitis: Lessons from COVID-19 and COVID-19 vaccination

Alberto Corrà  1 , Alice Verdelli  2 , Elena Biancamaria Mariotti  1 , Valentina Ruffo di Calabria  1 , Lavinia Quintarelli  2 , Cristina Aimo  1 , Cord H Sunderkötter  3 , Marzia Caproni  2
Affiliations
Review

Cutaneous vasculitis: Lessons from COVID-19 and COVID-19 vaccination

Alberto Corrà et al. Front Med (Lausanne). .

Abstract

Cutaneous vasculitis (CV) is an inflammatory skin-limited vascular disease affecting the dermal and/or hypodermal vessel wall. From the pathogenetic point of view, idiopathic forms are described as well as the induction from various triggers, such as drugs, infections, and vaccines. Following SARS-CoV-2 pandemic outbreak, cases of CV induced by both COVID-19 and COVID-19 vaccinations have been reported in literature. The aim of our work was to collect multiple cases available in the literature and analyze the frequency of the different forms of induced vasculitis, as well as their histological and immunopathological features. Although rare, CV induced by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and vaccines may provide interesting insights into the pathogenesis of these inflammatory processes that may in the future be useful to understand the mechanisms underlying cutaneous and systemic vasculitis.

Keywords: COVID-19; COVID-19 vaccines; IgA vasculitis; cutaneous vasculitis; leukocytoclastic vasculitis; urticarial vasculitis; vaccine-induced vasculitis; vasculitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A,B) Purpuric maculae and papules in the lower extremities in a patient with a recent anamnesis of COVID-19 vaccination. (C,D) Direct immunofluorescence performed on lesional skin, with evidence of perivascular deposition of C3. (c: 10% magnification, d: 20% magnification).
See this image and copyright information in PMC

References

    1. Caproni M, Verdelli A. An update on the nomenclature for cutaneous vasculitis. Curr Opin Rheumatol. (2019) 31:46–52. 10.1097/BOR.0000000000000563 - DOI - PubMed
    1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. . 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. (2013) 65:1–11. 10.1002/art.37715 - DOI - PubMed
    1. Sunderkötter CH, Zelger B, Chen KR, Requena L, Piette W, Carlson JA, et al. . Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheumatol. (2018) 70:171–84. 10.1002/art.40375 - DOI - PubMed
    1. Filosa A, Verdelli A, Bianchi B, Del Bianco E, Bugatti L, Filosa G, et al. . Cutaneous vasculitidis: histology and immunofluorescence. G Ital Dermatol Venereol. (2015) 150:183–91. - PubMed
    1. Morita TCAB, Criado PR, Criado RFJ, Trés GFS, Sotto MN. Update on vasculitis: overview and relevant dermatological aspects for the clinical and histopathological diagnosis - Part II. An Bras Dermatol. (2020) 95:493–507. 10.1016/j.abd.2020.04.004 - DOI - PMC - PubMed